Mineralys Therapeutics (MLYS) insider plans NASDAQ sale after option exercise

Rhea-AI Filing Summary

Mineralys Therapeutics, Inc. insider trading plan disclosure: A person named David Rodman has filed a notice of intent to sell 6,349 shares of Mineralys Therapeutics common stock on NASDAQ through Merrill Lynch, with an aggregate market value of 184,076.52. The filing notes 79,139,956 shares of common stock outstanding.

The 6,349 shares were acquired on 02/12/2026 via a broker-assisted cashless exercise of employee stock options. The form also lists prior sales of Mineralys Therapeutics common stock by David Rodman over the past three months, totaling several transactions with combined gross proceeds in the millions of dollars.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common stock	Merrill Lynch 225 Liberty St Floor 37 New York NY 10281	6349	184076.52	79139956	02/12/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common stock	02/12/2026	Exercise of employee stock options	Mineralys Therapeutics, Inc.			6349	02/12/2026	Broker assisted cashless exercise

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
David Rodman 150 N. RADNOR CHESTER ROAD SUITE F200 RADNOR PA 19087	Common stock	01/05/2026	192715	6749100.06
David Rodman 150 N. RADNOR CHESTER ROAD SUITE F200 RADNOR PA 19087	Common stock	01/02/2026	70037	2511919.03
David Rodman 150 N. RADNOR CHESTER ROAD SUITE F200 RADNOR PA 19087	Common stock	01/09/2026	2170	72195.90
David Rodman 150 N. RADNOR CHESTER ROAD SUITE F200 RADNOR PA 19087	Common stock	01/12/2026	6348	205142.99
David Rodman 150 N. RADNOR CHESTER ROAD SUITE F200 RADNOR PA 19087	Common stock	01/13/2026	7709	252469.75
David Rodman 150 N. RADNOR CHESTER ROAD SUITE F200 RADNOR PA 19087	Common stock	01/14/2026	11367	370645.39
David Rodman 150 N. RADNOR CHESTER ROAD SUITE F200 RADNOR PA 19087	Common Stock	01/20/2026	416	13353.60
David Rodman 150 N. RADNOR CHESTER ROAD SUITE F200 RADNOR PA 19087	Common Stock	02/09/2026	2171	65585.91

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 filing for MLYS disclose about planned stock sales?

The filing discloses an intended sale of 6,349 MLYS common shares. These shares have an aggregate market value of 184,076.52 and are planned to be sold on NASDAQ through Merrill Lynch, as part of a notice required when certain shareholders plan to sell restricted or control stock.

How were the 6,349 Mineralys Therapeutics (MLYS) shares being sold acquired?

The 6,349 MLYS shares were acquired through an employee stock option exercise. The filing states they were obtained on 02/12/2026 via an exercise of employee stock options from Mineralys Therapeutics, Inc., using a broker-assisted cashless exercise structure on the same date.

Who is selling Mineralys Therapeutics (MLYS) shares according to this Form 144?

David Rodman is the person for whose account the MLYS shares are to be sold. His name and address are listed both for the new planned sale and for multiple prior common stock sales reported over the last three months in the same notice.

How many Mineralys Therapeutics (MLYS) shares are outstanding in this Form 144?

The filing reports 79,139,956 MLYS common shares outstanding. This figure provides context for the planned sale of 6,349 shares, showing the overall size of the company’s equity base at the time referenced in the notice.

What previous Mineralys Therapeutics (MLYS) stock sales by David Rodman are listed?

The notice lists several MLYS common stock sales by David Rodman over three months. These include transactions on dates such as 01/02/2026, 01/05/2026, and 02/09/2026, with amounts ranging from hundreds to over 190,000 shares and gross proceeds in the millions.

What representation does the seller make about Mineralys Therapeutics (MLYS) information?

The seller represents that he does not know undisclosed material adverse information about MLYS. By signing, he affirms there is no non-public material adverse information regarding the issuer’s current or prospective operations in connection with the planned sale under Rule 144.